全国服务咨询热线：
18438616290
18438616290
产品分类
Product Category详细介绍
| 品牌 | absin | CAS | 164650-44-6 |
|---|---|---|---|
| 分子式 | C18H22F2N4O | 纯度 | 98% |
| 分子量 | 348.34 | 货号 | abs47027999 |
| 规格 | 10mg | 供货周期 | 现货 |
| 主要用途 | is a novel triazole antifungal drug | 应用领域 | 化工,生物产业,农林牧渔,制药/生物制药,综合 |
Efinaconazole 164650-44-6
| 产品描述 | |
| 描述 | Efinaconazole(KP-103) is a novel triazole antifungal drug currently under development as a topical treatment for onychomycosis. |
| 纯度 | 98% |
| 储存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 可溶性/溶解性 | 10 mM in DMSO |
| 生物活性 | |
| 靶点 | 14 alpha-demethylase |
| In vitro(体外研究) | In in vitro antifungal susceptibility tests, efinaconazole shows lower minimum inhibitory concentration (MIC) than terbinafine, ciclopirox, itraconazole and amorolfine. |
| In vivo(体内研究) | Efinaconazole is a topical antifungal, so it has relatively low systemic accumulation. The plasma half-life after 10 days of administration is 29.9 h. It has high plasma protein-binding affinity from 95.8 to 96.5%; primarily to albumin, a1-acid glycoprotein and γ-globulin. Efinaconazole is metabolized extensively through oxidative and reductive processes resulting in a sole H3 metabolite. It may also undergo glucuronidation. Efinaconazole does not have significant interactions with CYP450 enzymes in the liver. CYP2C8, CYP2C9, CYP2C19 and CYP3A4 are inhibited by efinaconazole at concentrations higher than the systemic concentrations achieved clinically. |
| 研究领域 | |
| 研究领域 | MetabolismTypes of disease Drug DiscoverySmall Molecule DrugLead Compound Discovery |
产品咨询
地址：上海市浦东新区新浩路58号申江科创园18栋
邮箱：lanwu@univ-bio.com
传真：